HER2 is an erbB/HER type 1 tyrosine kinase receptor that is frequently over-expressed in malignant epithelial tumours. Herceptin, a humanised mouse monoclonal antibody to HER2, is proven therapeutically in the management of metastatic breast cancer, significantly prolonging survival when combined wi
Identification of TDE2 gene and its expression in non-small cell lung cancer
✍ Scribed by Audrey Player; John Gillespie; Takeshi Fujii; Junya Fukuoka; Tatiana Dracheva; Dauod Meerzaman; Kyeong Man Hong; John Curran; Goziam Attoh; William Travis; Jin Jen
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- French
- Weight
- 336 KB
- Volume
- 107
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
TDE2, a gene with sequence similarity to the mouse testicular tumor‐differentially‐expressed (Tde1/MUSTETU) gene, was identified by serial analysis of gene expression (SAGE) in nonsmall cell lung cancers (NSCLC). Here we characterized the TDE2 gene and determined its transcript levels in a panel of lung tumors, adjacent nonmalignant lung tissues and a variety of normal human tissues. In addition, we show that TDE2 is a potential transmembrane protein with 11 putative transmembrane helices. Using real‐time quantitative PCR, we showed that TDE2 transcript levels were higher in NSCLC compared to nonmalignant samples. In nonpulmonary normal tissues, the level of TDE2 was the highest in bladder, kidney and muscle; moderate to low in stomach, liver, skin, placenta and ovary tissues; and undetectable in brain, spleen and heart. By in situ hybridization, we showed that 10 of 18 lung tumors and only 1 of 14 adjacent nonmalignant regions had high levels of TDE2 transcripts. Alternatively, only 2 of 18 tumors and 8 of 14 adjacent nonmalignant bronchiole epithelium regions demonstrated negative to low levels of TDE2 signals. © 2003 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Methylation‐associated inactivation of __RASSF1__, a putative tumor suppressor identified at 3p21.3, is reported in several cancers. We examined __RASSF1__ in non‐small lung cancer (NSCLC) to search for clinical implications. RT‐PCR analysis showed no expression of __RASSF1A__ in 12 of
Evidence for the existence of neuroendocrine (NE) differentiation in non-small cell lung carcinomas (NSCLCs) is at present based on histochemical, ultrastructural, and immunohistochemical data. The aim of this study was to investigate the extent of NE differentiation in NSCLCs as revealed by mRNA an
## Abstract Patients with lung cancer have a poor prognosis because of the high metastatic potential of the neoplasm. Therefore, identifying new molecular targets for anti‐metastatic therapy is very important. To identify novel key factors of tumor metastasis in lung cancer, we established the gene
In a comprehensive immunohistochemical study of the expression of ten metalloproteinases (MMPs) and their four inhibitors (TIMPs) in 115 non-small cell lung carcinomas (NSCLCs), the ®ndings have been correlated with the histological and clinical features of the tumours. All MMPs and TIMPs were expre
## Abstract Lung cancer is still the leading cause of death from cancer worldwide primarily because of the fact that most lung cancers are diagnosed at advanced stages. Overexpression of the high mobility group protein HMGA2 has been observed in a variety of malignant tumors and often correlates wi